Smartphone Measured Eye-Based Digital Biomarkers for Drug Use Detection

Informations projet

PrevictDrugs

N° de convention de subvention: 876553

DOI

10.3030/876553

Projet clôturé

Date de signature de la CE 2 Août 2019

Date de début 1 Septembre 2019

Date de fin 29 Février 2020

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

KONTIGO CARE AB
Sweden

Periodic Reporting for period 1 - PrevictDrugs (Smartphone Measured Eye-Based Digital Biomarkers for Drug Use Detection)

Période du rapport: 2019-09-01 au 2020-02-29

Résumé du contexte et des objectifs généraux du projet

Globally, 250 million have used drugs, 27 million suffer from problem drug use and 187,100 deaths occurred as a direct consequence of drug use. Thus, drug abuse needs to be controlled and monitored. Addiction treatments in the EU focus on out-patient relapse prevention strategies due to the limited healthcare resources at hand. However, for these approaches to become effective, daily, low-cost monitoring of sobriety and risk assessment of relapse are required. Current reaction times are too slow as caregivers lack tools to identify relapses in real-time. Consequently, there is an urgent need to change conservative approaches and improve treatment outcomes for the growing number of patients. The reach and speed of web and app applications are tremendous and timing and readiness for Europa’s Health care are optimal. This is the gap Kontigo Care aims to address through the SME Instrument project.

The overall objective of this project was to develop and optimize a business plan that will guide the development and commercialization of Kontigo Care’s Previct Drugs - a robust, app-based, eHealth-platform for continuous self-monitoring of drug use.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Kontigo Care performed the feasibility study which will guide the development, clinical validation and commercialisation of Previct Drugs. The study has provided a valuable understanding of the market, targeted users, competitive landscape, and regulatory pathways. The clinical evaluation plan has also been developed as a part of the project.

The feasibility study has confirmed a significant business opportunity within the global drug use monitoring market.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

This feasibility study has further confirmed the innovative character of Kontigo Care’s approach. Our Previct Drugs medical device will constitute an add-on to Kontigo Care’s current eHealth offer developed for the management of other addictive disorders (alcohol abuse and hazard gambling). On the patient’s side, the data will be collected with a smartphone app capable of measuring eye parameters – pupillometry-based method for monitoring the use of illicit drugs.

We strive to develop our prototype further and validate the potential for a medical device that will enable early therapeutic interventions, daily home-based therapeutic interventions and appropriate distribution of healthcare resources. Drug abuse is a serious global health problem and Kontigo Care is convinced its innovative approach will have a significant impact on the health-economic burden of drug abuse in Europe and worldwide.

Kontigo Care - mission statement